The University of Southampton
University of Southampton Institutional Repository

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study
Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study
Aim The aim of this study was to assess the impact of switching from immediate-release (IR) methylphenidate (MPH) to OROS® MPH (CONCERTA®), a once-daily long-acting MPH formulation, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods Subjects with ADHD aged 6–16 (n=105),who were stably maintained on their current IR MPH regimen (10–60 mg/day), were switched to 18, 36 or 54mg OROS® MPH once daily for 21 days, depending on pre-study daily MPH dose.ADHD symptoms were assessed by parents, teachers and investigators. Results By Day 21, parent/caregiver IOWA Conners ratings had decreased from baseline by 2.7 points to 5.2 (I/O), and by 1.8 points to 5.0 (O/D). Teacher IOWA Conners ratings were maintained. Decreases in IOWA Conners ratings are indicative of ADHD symptom improvement. Approximately 75% of parents and investigators rated therapy as good or excellent. OROS® MPH therapy was well tolerated. Conclusions Switching from IR MPH to OROS® MPH maintained and may have improved symptom control in children and adolescents with ADHD, during the course of this study. The changes in parent/caregiver IOWA Conners ratings suggest that OROS® MPH improves symptom control in the after-school period. This is consistent with the 12-h duration of action previously demonstrated for OROS® MPH.
ADHD, CONCERTA®, long-acting, methylphenidate, OROS®
1018-8827
297-304
Remschmidt, H.
777abe28-b7fe-4dd5-b31d-31a1e38e6051
Hoare, P.
bd0cbb54-8378-47fa-946e-6bf35a19bfc3
Ettrich, C.
c3f739e3-b273-4912-88ba-e05619d5b9ff
Rothenberger, A.
f946fbda-7ceb-46b0-b48d-23cdaa4016aa
Santosh, P.
83759ca4-e254-4733-be8d-df022df6ce89
Schmidt, M.
68f4851a-9b14-48a9-b08f-854618465310
Spender, Q.
d00dc50d-3116-40a9-8c9b-f9231e893d9d
Tamhne, R.
13a55c60-5f75-4ef7-96bc-43ed88fe95d6
Thompson, M.
bfe8522c-b252-4771-8036-744e93357c67
Tinline, C.
2aa195bb-e46e-4ee4-96d7-3b4d64597ab9
Trott, G.E.
538e7045-7fa7-45c7-bd87-59271ea29930
Medori, R.
2a565b97-0e25-4133-a25e-66d1f6f6df54
Remschmidt, H.
777abe28-b7fe-4dd5-b31d-31a1e38e6051
Hoare, P.
bd0cbb54-8378-47fa-946e-6bf35a19bfc3
Ettrich, C.
c3f739e3-b273-4912-88ba-e05619d5b9ff
Rothenberger, A.
f946fbda-7ceb-46b0-b48d-23cdaa4016aa
Santosh, P.
83759ca4-e254-4733-be8d-df022df6ce89
Schmidt, M.
68f4851a-9b14-48a9-b08f-854618465310
Spender, Q.
d00dc50d-3116-40a9-8c9b-f9231e893d9d
Tamhne, R.
13a55c60-5f75-4ef7-96bc-43ed88fe95d6
Thompson, M.
bfe8522c-b252-4771-8036-744e93357c67
Tinline, C.
2aa195bb-e46e-4ee4-96d7-3b4d64597ab9
Trott, G.E.
538e7045-7fa7-45c7-bd87-59271ea29930
Medori, R.
2a565b97-0e25-4133-a25e-66d1f6f6df54

Remschmidt, H., Hoare, P., Ettrich, C., Rothenberger, A., Santosh, P., Schmidt, M., Spender, Q., Tamhne, R., Thompson, M., Tinline, C., Trott, G.E. and Medori, R. (2005) Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study. European Child & Adolescent Psychiatry, 14 (6), 297-304. (doi:10.1007/s00787-005-0467-6).

Record type: Article

Abstract

Aim The aim of this study was to assess the impact of switching from immediate-release (IR) methylphenidate (MPH) to OROS® MPH (CONCERTA®), a once-daily long-acting MPH formulation, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods Subjects with ADHD aged 6–16 (n=105),who were stably maintained on their current IR MPH regimen (10–60 mg/day), were switched to 18, 36 or 54mg OROS® MPH once daily for 21 days, depending on pre-study daily MPH dose.ADHD symptoms were assessed by parents, teachers and investigators. Results By Day 21, parent/caregiver IOWA Conners ratings had decreased from baseline by 2.7 points to 5.2 (I/O), and by 1.8 points to 5.0 (O/D). Teacher IOWA Conners ratings were maintained. Decreases in IOWA Conners ratings are indicative of ADHD symptom improvement. Approximately 75% of parents and investigators rated therapy as good or excellent. OROS® MPH therapy was well tolerated. Conclusions Switching from IR MPH to OROS® MPH maintained and may have improved symptom control in children and adolescents with ADHD, during the course of this study. The changes in parent/caregiver IOWA Conners ratings suggest that OROS® MPH improves symptom control in the after-school period. This is consistent with the 12-h duration of action previously demonstrated for OROS® MPH.

Full text not available from this repository.

More information

Published date: September 2005
Keywords: ADHD, CONCERTA®, long-acting, methylphenidate, OROS®

Identifiers

Local EPrints ID: 58925
URI: http://eprints.soton.ac.uk/id/eprint/58925
ISSN: 1018-8827
PURE UUID: 73038f67-0cf3-430f-986d-69d4ee1ab3c6

Catalogue record

Date deposited: 19 Aug 2008
Last modified: 13 Mar 2019 20:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×